Trexquant Investment’s Palvella Therapeutics PVLA Stock Holding History

Trexquant Investment’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Sell	13,495 -23,144	-63%	-$2.81M	0.01%	1179
2026 Q1	$4.57M	Buy	+36,639	New	+$3.82M	0.03%	685
2018 Q4	–	Sell	-612	Closed	-$274K	–	1355
2018 Q3	$274K	Buy	612 +333	+119%	+$145K	0.02%	716
2018 Q2	$113K	Sell	279 -864	-76%	-$411K	0.01%	831
2018 Q1	$624K	Buy	1,143 +646	+130%	+$400K	0.04%	560
2017 Q4	$300K	Buy	+497	New	+$231K	0.03%	749

Other funds holding PVLA

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Trexquant Investment's PVLA Position: Q2 2026 in Review

Trexquant Investment reduced its Palvella Therapeutics (PVLA) stake by 63% in Q2 2026, selling an estimated $2.81M and leaving 13,495 shares worth $2.06M. The position accounts for 0.01% of the portfolio, ranked #1179.

Trexquant Investment first reported a position in PVLA in Q4 2017 and has held it in 6 quarters since. The position peaked at $4.57M in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

Trexquant Investment held 13,495 shares of Palvella Therapeutics worth $2.06M as of Q2 2026.
Trexquant Investment sold 23,144 Palvella Therapeutics shares in Q2 2026, an estimated $2.81M.
Palvella Therapeutics made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1179 holding.
Trexquant Investment first reported a position in Palvella Therapeutics in Q4 2017 and has held it in 6 quarters since.
Trexquant Investment's Palvella Therapeutics position peaked at $4.57M in Q1 2026.
197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.